Symbiosis bolsters in-house analytical testing with £1M investment
The investment will give Symbiosis greater control over sample testing timelines
Symbiosis Pharmaceutical Services, a UK-headquartered contract manufacturing organisation (CMO) that provides GMP aseptic fill and finish services, is expanding its in-house analytical testing capabilities with a £1 million investment.
This investment will see the introduction of in-house testing capabilities for both analytical chemistry and microbiology, and will include dedicated microbiology laboratories as well as temperature and humidity-controlled stability storage capabilities. These will be located adjacent to the company’s existing GMP manufacturing suites in Stirling, Scotland.
Construction of the laboratories began in June of this year and the first microbiology testing capabilities will be qualified and available to support an international client base from the first quarter of 2023. Further microbiology and chemistry capabilities will be qualified and introduced throughout 2023.
Symbiosis also announced the appointment of Alison Clayton as Head of Analytical Services to lead the expansion of analytical testing capabilities. She said the company would take a phased approach to building in-house chemistry and microbiology laboratory capabilities and will eventually offer ‘an enhanced suite of testing capabilities, including sterility, bioburden and endotoxin testing as well as analytical chemistry.’
The company is expected to hire up to 20 additional skilled life sciences staff by the end of next year to support this new testing capability.
CEO of Symbiosis, Colin MacKay commented: ‘This investment is another clear statement of our continuing ambition to strengthen our service offering in response to the demands from existing clients and to position Symbiosis to attract further global biotechnology and pharmaceutical clients in the future.’
The new laboratories will be located in the Logie Court building, one of the three buildings on the Stirling Innovation Park in the UK from which Symbiosis operates.
Related News
-
News Lonza and Touchlight collaboration to bring expanded end-to-end mRNA offerings
Through a collaboration with biotech company Touchlight, Lonza is set to expand their end-to-end offering for mRNA manufacturing with additional DNA raw material sources, including Touchlight’s doggybone DNA. -
News Oxford University presents promising phase II data for malaria vaccine
The malaria vaccine R21/Matrix-M, developed by researchers at Oxford University, has produced encouraging new data for the global effort against the mosquito-borne disease. -
News NextPharma to acquire Norway manufacturing site from Takeda
Biopharmaceutical company Takeda and CDMO NextPharma have announced an acquisition agreement in which Takeda will divest from their Asker, Norway manufacturing site, set to be acquired by NextPharma. -
News Novavax COVID-19 vaccine receives backing from European Medicines Agency
The European Medicines Agency has backed the Nuvaxovid COVID-19 vaccine for adults as a booster shot to other COVID-19 vaccines. -
News Moderna sues Pfizer/BioNTech over COVID-19 vaccine patent infringement
The pharmaceutical companies behind the leading COVID-19 vaccines are in a legal dispute over intellectual property rights surrounding the mRNA vaccines that were released after emergency use authorization in December 2020. -
News Accepting novel excipients for innovative drug development
With the rapid development and manufacturing of new drugs and therapeutics being pushed through the pipeline, excipient manufacturers are navigating a challenging landscape to meet the demand for new and novel excipients. -
News ChargePoint Technology acquires PuroVaso for greater range of powder and liquid transfer solutions
ChargePoint Technology has acquired PuroVaso, leader in the design, development, and manufacture of single-use containers, handling equipment, and accessories for pharma, biopharma, and life sciences. -
News Lonza adds X-ray powder diffraction to micronisation portfolio in Monteggio (CH)
Lonza expands solid-state characterisation services for polymorph and solid-state properties of APIs with the addition of X-ray powder diffraction to its portfolio.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance